# Travere Therapeutics (TVTX) — Earnings

TVTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tvtx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.37 |
| EPS estimate | −$0.13 |
| EPS surprise | −174.68% |
| Revenue surprise | +7.83% |
| Revenue | $169.6M |
| Revenue estimate | $157.3M |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1438533/000143853326000063/tvtx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/704945e9-2f51-0e9d-9d45-c2fc3568da08.html) |

Travere Therapeutics reported Q2 2026 results on August 4, 2026. It posted a loss of $0.37 per share, wider than the expected loss of $0.13, a 174.68% miss. Revenue was $169.6 million, about 8% above the $157.3 million consensus. Compared with Q2 2025, the loss widened from $0.14 per share, while revenue rose about 79% from $94.8 million.

Losses run through most of the table. Travere lost money in 17 of the last 20 quarters, with annual losses of $4.37 per share in 2022, $1.61 in 2023 and $4.10 in 2024. The three profitable quarters were Q3 2023 at $1.97, Q3 2025 at $0.28 and Q4 2025 at $0.03. That brought the 2025 loss down to $0.30 per share. Revenue was roughly flat at $193 million to $232 million a year from 2022 to 2024, then about doubled to $465.3 million in 2025. Q2 2026 is the revenue high in the table. Travere beat the EPS estimate 6 times in 20 quarters.

The company reported Q3 between October 27 and November 7 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue growth continues.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | −$0.13 | −$0.37 | -174.68% | $157.3M | $169.6M |
| Q1 2026 | May 4, 2026 | −$0.24 | −$0.40 | -65.29% | $136.2M | $127.2M |
| Q4 2025 | Feb 19, 2026 | $0.00 | $0.03 | 1150.00% | $147.5M | $129.7M |
| Q3 2025 | Oct 30, 2025 | −$0.30 | $0.28 | 192.20% | $105.2M | $164.9M |
| Q2 2025 | Aug 6, 2025 | −$0.31 | −$0.14 | 55.09% | $99.5M | $94.8M |
| Q1 2025 | May 1, 2025 | −$0.57 | −$0.47 | 17.11% | $77.3M | $75.9M |
| Q4 2024 | Feb 20, 2025 | −$0.56 | −$0.73 | -29.89% | $73.1M | $73.5M |
| Q3 2024 | Oct 31, 2024 | −$0.67 | −$0.70 | -4.62% | $60.9M | $62.9M |
| Q2 2024 | Aug 1, 2024 | −$0.79 | −$0.91 | -15.04% | $50.4M | $54.1M |
| Q1 2024 | May 6, 2024 | −$0.96 | −$1.76 | -83.60% | $43.5M | $41.4M |
| Q4 2023 | Feb 15, 2024 | −$1.16 | −$1.18 | -1.94% | $41.7M | $45.1M |
| Q3 2023 | Nov 7, 2023 | −$1.06 | $1.97 | 285.08% | $57.3M | $33.9M |
| Q2 2023 | Aug 3, 2023 | −$1.09 | −$1.13 | -3.80% | $53.6M | $57.0M |
| Q1 2023 | May 4, 2023 | −$1.20 | −$1.27 | -5.77% | $50.6M | $57.0M |
| Q4 2022 | Feb 23, 2023 | −$1.13 | −$1.03 | 9.17% | $53.0M | $55.9M |
| Q3 2022 | Oct 27, 2022 | −$0.95 | −$1.09 | -15.00% | $54.1M | $53.5M |
| Q2 2022 | Aug 4, 2022 | −$0.94 | −$1.05 | -11.83% | $49.6M | $51.0M |
| Q1 2022 | May 5, 2022 | −$0.87 | −$1.20 | -37.93% | $52.2M | $48.5M |
| Q4 2021 | Feb 24, 2022 | −$0.74 | −$0.84 | -14.18% | $57.8M | $57.2M |
| Q3 2021 | Oct 28, 2021 | −$0.56 | −$0.59 | -5.04% | $60.9M | $68.2M |

## Frequently Asked Questions

### When did Travere Therapeutics (TVTX) last report earnings?

Travere Therapeutics last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did TVTX beat earnings estimates?

No. Travere Therapeutics reported EPS of −$0.37 for Q2 2026 against a −$0.13 estimate — a 174.68% miss.

### How much revenue did TVTX report last quarter?

Travere Therapeutics reported $169.6M in revenue for Q2 2026, against a consensus estimate of $157.3M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).